Drug Metabolism
Drug Metabolism - Related Videos
06:50
Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
0 Views •
Cited by 1 •
2025
Here, we establish a metabolic profiling platform integrating three-dimensional (3D) glioma spheroids and imaging-based normalization via extracellular flux analysis. This approach enables more accurate assessment of tumor metabolic responses to drug treatments and provides insights into potential mechanisms of resistance.
01:17
Drug Metabolism: Phase I Reactions
0 Views •
2023
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
01:14
Drug Metabolism: Phase II Reactions
0 Views •
2023
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
01:27
Pharmacogenetics of Drug Metabolism: Overview
0 Views •
2026
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:24
Pharmacokinetics in Pediatric Patients: Drug Metabolism
0 Views •
2025
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
FAQs
Phase I reactions chemically modify a drug, commonly through oxidation performed by cytochrome P450 enzymes. Phase II reactions then attach polar groups to the resulting metabolite. This second change generally increases water solubility, making elimination more feasible. Examining both stages helps researchers determine whether a compound is inactivated, transformed into an active product, or prepared for excretion.
Metabolism changes the chemical form of a pharmaceutical compound, so the resulting metabolite may not behave like the starting drug. The transformation can reduce activity, preserve or create activity in a prodrug, or generate a metabolite with distinct effects or toxicity. Consequently, safety and therapeutic evaluations must consider metabolites as well as the administered compound.
Cytochrome P450 proteins commonly carry out Phase I reactions, particularly oxidation. By modifying pharmaceutical compounds, these enzymes influence which metabolites form and how the original drug's activity changes. Their role makes enzyme-mediated transformation important when researchers assess pharmacokinetics, estimate how long activity may persist, and investigate drug interactions during therapeutic development.
Attaching a polar group during a Phase II reaction makes a metabolite more water-soluble. That altered chemical property supports the body's ability to eliminate the compound, linking molecular transformation with clearance from the body. Researchers therefore examine Phase II processing when evaluating whether metabolism can move a drug or metabolite toward excretion.
Metabolic transformations help determine how long a drug remains active and how it is eliminated. By examining the formation and handling of metabolites, researchers can assess the compound's pharmacokinetic behavior, meaning its movement and persistence in the body. These findings support predictions about dosing requirements and help guide decisions during therapeutic development.
Metabolism can deactivate a drug, activate a prodrug, or produce a metabolite with different effects or toxicity. Each outcome can change the relationship between an administered dose and its biological consequences. Researchers use metabolic information to optimize dosing, balancing the desired therapeutic activity with the compound's persistence, elimination, and potential safety concerns.
Because enzymes transform pharmaceutical compounds, metabolic pathways are relevant when researchers evaluate whether one treatment could alter the handling or effects of another. Studying these transformations contributes to drug-interaction assessment alongside pharmacokinetic analysis. The results can reveal whether metabolism may change drug activity, persistence, elimination, or the properties of generated metabolites.
A drug's transformation does not guarantee that all resulting products are harmless or inactive. Metabolism may generate metabolites with distinct effects or toxicity, even when the original compound has a different profile. Evaluating these products therefore supports safety assessment and helps researchers judge whether a candidate's therapeutic potential is appropriate for further development.